Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis?
A 33-year-old male came to Policlinic of Hematology-Medical Oncology Dr. Cipto Mangunkusumo General Hospital for routine control of chronic myeloid leukemia (CML) treatment. He was treated with Imatinib Mesylate (IM) for two years. At the beginning of therapy, he showed good treatment response. Howe...
Saved in:
Main Authors: | Wulyo Rajabto (Author), Noviana Joenputri (Author) |
---|---|
Format: | Book |
Published: |
Interna Publishing,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Priapismus as Leukostasis Manifestation in Chronic Myeloid Leukemia
by: Wulyo Rajabto, et al.
Published: (2020) -
Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
by: Smeeta GAJENDRA, et al.
Published: (2019) -
Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia
by: Marta Romo-González, et al.
Published: (2020) -
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
by: El Rassi F, et al.
Published: (2013) -
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
by: Tiziana Grafone, et al.
Published: (2012)